Previous 10 | Next 10 |
Compugen Doses First Patient in COM701/Opdivo® (nivolumab) Phase 1b Cohort Expansion Study - Study builds upon signals of durable antitumor activity in extensively pretreated patients, including a confirmed complete response in the dose escalation arm - Biomarker-inform...
Compugen Presents Research Supporting PVRIG as a Novel and Differentiated Checkpoint in the DNAM-1 Axis - Research will be presented at the 2021 SITC's Targets for Cancer Immunotherapy: A Deep Dive Seminar Series PR Newswire HOLON, Israel , June 29, 2021 /PRN...
Gainers: Kaleido Biosciences (KLDO) +15%, Pieris Pharmaceuticals (PIRS) +14%, Arcus Biosciences (RCUS) +14%, Compugen (CGEN) +14%, Atossa Therapeutics (ATOS) +14%.Losers: Portage Biotech (PRTG) -23%, Rite Aid (RAD) -14%, 4D Mole...
Compugen (CGEN) jumped 5.3% on some takeover speculation following GlaxoSmithKline's (GSK) agreement with iTeos Therapeutics (ITOS) to jointly develop and commercialize EOS-448 an anti-TIGIT monoclonal antibody currently undergoing Phase 1 studies as a potential cancer therapy....
Compugen (CGEN) presents updated data from its Phase 1 study of COM701 as a monotherapy, and in combination study with Opdivo (nivolumab) at the ASCO 2021 Annual Meeting. Data highlights are with a cut-off of April 15 2021.COM701 and Opdivo combination: In 15 evaluable patients, COM701 i...
Compugen Announces Updated Data from Phase 1 Study of COM701, First- in-Class Anti-PVRIG, at the ASCO 2021 Annual Meeting Data show ongoing durable responses beyond one year in monotherapy and in combination with Opdivo® in heavily pre-treated patients including one patient...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead Meme stocks will be watched closely again with some investors still looking for an easy ride. As part of a heat check on...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Compugen Management to Discuss COM701 Data Presented at ASCO at Event Hosted by Truist Securities Vitual fireside chat with members of Compugen's management team will take place on June 8 at 12:00 PM ET PR Newswire HOLON, Israel , June 1, 2021 /PRNewswire/ --...
News, Short Squeeze, Breakout and More Instantly...
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors PR Newswire FDA clearance triggers a $30 million milestone payment from Gilead Company on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harne...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target ...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...